Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BCL9 | O00512 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773341 | 0.90 | BCL9 (0.46) | POLBMEN1KMT2APLK1CXCR2 | |
| SCHEMBL25501940 | 0.83 | CYP1A2 (0.50) | POLBMEN1KMT2ACXCR2MAPT | |
| SCHEMBL2773108 | 0.83 | MAPT (0.57) | POLBMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL2775099 | 0.81 | POLB (0.45) | POLBMEN1KMT2ACXCR2MAPT | |
| SCHEMBL2772692 | 0.81 | POLB (0.49) | POLBMEN1KMT2ACXCR2MAPT | |
| SCHEMBL2770446 | 0.81 | POLB (0.47) | POLBMEN1KMT2ACXCR2MAPT | |
| SCHEMBL2994041 | 0.81 | POLB (0.45) | POLBMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL2990917 | 0.81 | KMT2A (0.81) | POLBMEN1KMT2AMAPTIDO1 | |
| SCHEMBL7785565 | 0.81 | KMT2A (0.60) | POLBMEN1KMT2AMAPTMAPK1 | |
| SCHEMBL6549773 | 0.80 | POLB (0.68) | POLBMEN1KMT2APLK1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240255495-A1 | COVALENT APTAMERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-08-01 | — | — | US | claimed |
| WO-2022232195-A2 | COVALENT APTAMERS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-11-03 | — | — | WO | claimed |
| US-20260028321-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-29 | — | — | US | disclosed |
| CN-120077027-A | Sulfonylimide compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2025-05-30 | — | — | CN | disclosed |
| EP-4504713-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2025-02-12 | — | — | EP | disclosed |
| CN-119233968-A | 1,3, 4-Oxadiazole derivative compounds as histone deacetylase 6 inhibitors and uses thereof | 株式会社钟根堂 | 2024-12-31 | — | — | CN | disclosed |
| US-20240286994-A1 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2024-08-29 | — | — | US | disclosed |
| US-20240261249-A1 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2024-08-08 | — | — | US | disclosed |
| WO-2023195809-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023195809-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-10-12 | — | — | WO | disclosed |
| CN-112759549-B | 3-substituted amino-4- ((substituted pyridinyl) amino) cyclobut-3-ene-1, 2-dione compounds | 中国医学科学院药物研究所 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022255770-A1 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | 부산대학교 산학협력단 | 2022-12-08 | — | — | WO | disclosed |
| WO-2021150697-A1 | N-SUBSTITUTED-3-TRICYCLYL PIPERIDINE DERIVATIVES AS ANTICANCER AND NEUROPROTECTIVE AGENTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-07-29 | — | — | WO | disclosed |
| CN-112759549-A | 3-substituted amino-4- ((substituted pyridyl) amino) cyclobut-3-ene-1, 2-diones | 中国医学科学院药物研究所 | 2021-05-07 | — | — | CN | disclosed |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028321-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | HDAC6, HDAC1, HDAC3 | POLB 2187/4885MEN1 3823/4885KMT2A 133/4885 |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | POLB 273/4885MEN1 1932/4885KMT2A 1935/4885 |
| US-20240286994-A1 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | EIF3E, EIF3A, EIF3K | POLB 2038/4885MEN1 3731/4885KMT2A 1471/4885 |
| US-20240261249-A1 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | EIF3E, EIF3A, EIF3K | POLB 2038/4885MEN1 3731/4885KMT2A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.